Wisp is future-proofing women.
What’s happening: The women’s telehealth brand partnered with Vesalius Longevity Labs to develop exclusive peptide therapies for female longevity.
Priming. Starting in women’s reproductive health, Wisp has served 1.5M US patients across at-home STI diagnostics, cash-pay GLP-1s, and sexual wellness products sold via TikTok Shop.
Reaching an $80M run rate and growing 70% YoY, the company is extending into longevity, selling branded creatine and collagen supplements alongside Stripes menopause beauty products.
Fresh pep. Tapping Peptual parent Vesalius, Wisp will roll out injectables, patches, pills, and topicals supporting hormones, inflammation, and metabolism — adopting AI tools to guide prescriptions.
New stack. Sought after for performance, vitality, and weight loss, the global peptide therapeutics market will top $106B by 2033. Gaining clinical validation, female-specific formulations are merging longevity and menopause care. Already at work, Midi launched labs to tailor rejuvenation therapies.
Punchline: With peptides as a wedge, Wisp’s longevity play challenges rival Hers and aims to lock in female consumers for life.
